Xultophy® (insulin degludec/liraglutide; IDegLira) is cost-effective versus current basal insulin intensification in people with uncontrolled type 2 diabetes in the UK
Glasgow, Scotland (ots/PRNewswire) - This material is intended for European and UK medical media only. For journalistic assessment and preparation before publication. New findings show that Xultophy® (insulin degludec/liraglutide; IDegLira), the first once-daily combination of a long-acting basal insulin ...